Lexicon Pharmaceuticals' 'Into the Dark' campaign seeks to raise awareness among HCPs about the risks for recently-discharged heart failure patients

March 6, 2023 02:36 PM ESTUpdated 03:28 PM

Marketing

Lexicon dives ‘into the dark’ days following heart failure hospitalizations with new campaign

Beth Snyder Bulik

Senior Editor

Studies have shown that for heart failure patients, the period after leaving the hospital is a risky time for recurrence. Lexicon Pharmaceuticals wants healthcare providers …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Lexicon dives ‘into the dark’ days following heart failure hospitalizations with new campaign

Beth Snyder Bulik

Senior Editor

Sign up to read this article for free.

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Patient dies in Neurogene's Rett syndrome study

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Halozyme withdraws Evotec acquisition proposal after biotech is 'unwilling to engage'

Are programs with compounded GLP-1s safe for your population?

Lex­i­con dives ‘in­to the dark’ days fol­low­ing heart fail­ure hos­pi­tal­iza­tions with new cam­paign

Beth Snyder Bulik

Senior Editor

Sign up to read this article for free.

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Halozyme with­draws Evotec ac­qui­si­tion pro­pos­al af­ter biotech is 'un­will­ing to en­gage'

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

Lexicon dives ‘into the dark’ days following heart failure hospitalizations with new campaign

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Patient dies in Neurogene's Rett syndrome study

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Halozyme withdraws Evotec acquisition proposal after biotech is 'unwilling to engage'

Are programs with compounded GLP-1s safe for your population?